WO2007139982A2 - Methods and compositions for gene inactivation - Google Patents
Methods and compositions for gene inactivation Download PDFInfo
- Publication number
- WO2007139982A2 WO2007139982A2 PCT/US2007/012588 US2007012588W WO2007139982A2 WO 2007139982 A2 WO2007139982 A2 WO 2007139982A2 US 2007012588 W US2007012588 W US 2007012588W WO 2007139982 A2 WO2007139982 A2 WO 2007139982A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- cells
- gene
- ccr5
- domain
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 65
- 108090000623 proteins and genes Proteins 0.000 title claims description 143
- 239000000203 mixture Substances 0.000 title abstract description 19
- 230000002779 inactivation Effects 0.000 title description 5
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 141
- 230000007017 scission Effects 0.000 claims abstract description 141
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims abstract description 125
- 239000013598 vector Substances 0.000 claims abstract description 117
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 35
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 35
- 239000002157 polynucleotide Substances 0.000 claims abstract description 35
- 101710185494 Zinc finger protein Proteins 0.000 claims abstract description 31
- 102100023597 Zinc finger protein 816 Human genes 0.000 claims abstract description 31
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 21
- 230000000415 inactivating effect Effects 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 260
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 77
- 102000004169 proteins and genes Human genes 0.000 claims description 64
- 230000027455 binding Effects 0.000 claims description 56
- 150000007523 nucleic acids Chemical class 0.000 claims description 54
- 102000039446 nucleic acids Human genes 0.000 claims description 47
- 108020004707 nucleic acids Proteins 0.000 claims description 47
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 39
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 37
- 229920001184 polypeptide Polymers 0.000 claims description 37
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 37
- 239000011701 zinc Substances 0.000 claims description 37
- 229910052725 zinc Inorganic materials 0.000 claims description 37
- 101150017501 CCR5 gene Proteins 0.000 claims description 27
- 230000004568 DNA-binding Effects 0.000 claims description 17
- 208000031886 HIV Infections Diseases 0.000 claims description 14
- 208000037357 HIV infectious disease Diseases 0.000 claims description 14
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 14
- 210000004443 dendritic cell Anatomy 0.000 claims description 9
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 9
- 210000002540 macrophage Anatomy 0.000 claims description 8
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 7
- 238000001476 gene delivery Methods 0.000 claims description 6
- 210000005260 human cell Anatomy 0.000 claims description 6
- 108010017070 Zinc Finger Nucleases Proteins 0.000 abstract description 128
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 99
- 239000002773 nucleotide Substances 0.000 description 57
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 56
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 56
- 125000003729 nucleotide group Chemical group 0.000 description 54
- 108020004414 DNA Proteins 0.000 description 53
- 208000015181 infectious disease Diseases 0.000 description 48
- 108700028369 Alleles Proteins 0.000 description 33
- 101710163270 Nuclease Proteins 0.000 description 30
- 230000014509 gene expression Effects 0.000 description 28
- 230000035772 mutation Effects 0.000 description 27
- 238000003780 insertion Methods 0.000 description 25
- 230000037431 insertion Effects 0.000 description 25
- 150000001413 amino acids Chemical group 0.000 description 23
- 238000009396 hybridization Methods 0.000 description 23
- 238000003556 assay Methods 0.000 description 22
- 108020001507 fusion proteins Proteins 0.000 description 18
- 102000037865 fusion proteins Human genes 0.000 description 18
- 239000000523 sample Substances 0.000 description 18
- 108010077544 Chromatin Proteins 0.000 description 17
- 210000003483 chromatin Anatomy 0.000 description 17
- 238000013461 design Methods 0.000 description 17
- 230000004927 fusion Effects 0.000 description 17
- 238000010361 transduction Methods 0.000 description 16
- 230000001404 mediated effect Effects 0.000 description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- 230000001413 cellular effect Effects 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 238000012239 gene modification Methods 0.000 description 13
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 239000011324 bead Substances 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 238000012546 transfer Methods 0.000 description 12
- 238000012217 deletion Methods 0.000 description 11
- 230000037430 deletion Effects 0.000 description 11
- 230000006780 non-homologous end joining Effects 0.000 description 11
- 108091008146 restriction endonucleases Proteins 0.000 description 11
- 108010042407 Endonucleases Proteins 0.000 description 10
- 102000004533 Endonucleases Human genes 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 210000000130 stem cell Anatomy 0.000 description 10
- 108091026890 Coding region Proteins 0.000 description 9
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 9
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 230000005782 double-strand break Effects 0.000 description 9
- -1 for example Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 230000002458 infectious effect Effects 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 231100000350 mutagenesis Toxicity 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 238000002744 homologous recombination Methods 0.000 description 8
- 230000006801 homologous recombination Effects 0.000 description 8
- 230000010354 integration Effects 0.000 description 8
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 7
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 7
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 7
- 229930182816 L-glutamine Natural products 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 230000026683 transduction Effects 0.000 description 7
- 101100438883 Homo sapiens CCR5 gene Proteins 0.000 description 6
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 238000000137 annealing Methods 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000002688 persistence Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000006798 recombination Effects 0.000 description 6
- 238000005215 recombination Methods 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000002103 transcriptional effect Effects 0.000 description 6
- 108700019146 Transgenes Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000012937 correction Methods 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000001052 transient effect Effects 0.000 description 5
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000508269 Psidium Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000010415 tropism Effects 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 230000007018 DNA scission Effects 0.000 description 3
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- 102000011931 Nucleoproteins Human genes 0.000 description 3
- 108010061100 Nucleoproteins Proteins 0.000 description 3
- 108010047956 Nucleosomes Proteins 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 102000023732 binding proteins Human genes 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000004970 cd4 cell Anatomy 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000006471 dimerization reaction Methods 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 210000001623 nucleosome Anatomy 0.000 description 3
- 210000004287 null lymphocyte Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000010187 selection method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000007502 viral entry Effects 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 101710145505 Fiber protein Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 101000687346 Homo sapiens PR domain zinc finger protein 2 Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 241000701124 Human adenovirus 35 Species 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 101150008942 J gene Proteins 0.000 description 2
- 206010024305 Leukaemia monocytic Diseases 0.000 description 2
- 108091036060 Linker DNA Proteins 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 102100024885 PR domain zinc finger protein 2 Human genes 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010042566 Superinfection Diseases 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 108091092356 cellular DNA Proteins 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000003763 chloroplast Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 201000006894 monocytic leukemia Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 230000000174 oncolytic effect Effects 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 102000021127 protein binding proteins Human genes 0.000 description 2
- 108091011138 protein binding proteins Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 101150096316 5 gene Proteins 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- 101000768957 Acholeplasma phage L2 Uncharacterized 37.2 kDa protein Proteins 0.000 description 1
- 101000823746 Acidianus ambivalens Uncharacterized 17.7 kDa protein in bps2 3'region Proteins 0.000 description 1
- 101000916369 Acidianus ambivalens Uncharacterized protein in sor 5'region Proteins 0.000 description 1
- 101000769342 Acinetobacter guillouiae Uncharacterized protein in rpoN-murA intergenic region Proteins 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- 101000823696 Actinobacillus pleuropneumoniae Uncharacterized glycosyltransferase in aroQ 3'region Proteins 0.000 description 1
- 101000786513 Agrobacterium tumefaciens (strain 15955) Uncharacterized protein outside the virF region Proteins 0.000 description 1
- 101000618005 Alkalihalobacillus pseudofirmus (strain ATCC BAA-2126 / JCM 17055 / OF4) Uncharacterized protein BpOF4_00885 Proteins 0.000 description 1
- 102100020724 Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Human genes 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 101100272917 Arabidopsis thaliana ZFN2 gene Proteins 0.000 description 1
- 101000967489 Azorhizobium caulinodans (strain ATCC 43989 / DSM 5975 / JCM 20966 / LMG 6465 / NBRC 14845 / NCIMB 13405 / ORS 571) Uncharacterized protein AZC_3924 Proteins 0.000 description 1
- 101000823761 Bacillus licheniformis Uncharacterized 9.4 kDa protein in flaL 3'region Proteins 0.000 description 1
- 101000819719 Bacillus methanolicus Uncharacterized N-acetyltransferase in lysA 3'region Proteins 0.000 description 1
- 101000789586 Bacillus subtilis (strain 168) UPF0702 transmembrane protein YkjA Proteins 0.000 description 1
- 101000792624 Bacillus subtilis (strain 168) Uncharacterized protein YbxH Proteins 0.000 description 1
- 101000790792 Bacillus subtilis (strain 168) Uncharacterized protein YckC Proteins 0.000 description 1
- 101000819705 Bacillus subtilis (strain 168) Uncharacterized protein YlxR Proteins 0.000 description 1
- 101000948218 Bacillus subtilis (strain 168) Uncharacterized protein YtxJ Proteins 0.000 description 1
- 101000718627 Bacillus thuringiensis subsp. kurstaki Putative RNA polymerase sigma-G factor Proteins 0.000 description 1
- 101000641200 Bombyx mori densovirus Putative non-structural protein Proteins 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 101000947633 Claviceps purpurea Uncharacterized 13.8 kDa protein Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101000948901 Enterobacteria phage T4 Uncharacterized 16.0 kDa protein in segB-ipI intergenic region Proteins 0.000 description 1
- 101000805958 Equine herpesvirus 4 (strain 1942) Virion protein US10 homolog Proteins 0.000 description 1
- 101000790442 Escherichia coli Insertion element IS2 uncharacterized 11.1 kDa protein Proteins 0.000 description 1
- 101000788354 Escherichia phage P2 Uncharacterized 8.2 kDa protein in gpA 5'region Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 101000770304 Frankia alni UPF0460 protein in nifX-nifW intergenic region Proteins 0.000 description 1
- 101000797344 Geobacillus stearothermophilus Putative tRNA (cytidine(34)-2'-O)-methyltransferase Proteins 0.000 description 1
- 101000748410 Geobacillus stearothermophilus Uncharacterized protein in fumA 3'region Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 101000772675 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) UPF0438 protein HI_0847 Proteins 0.000 description 1
- 101000631019 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Uncharacterized protein HI_0350 Proteins 0.000 description 1
- 101000768938 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.9 kDa protein in int-C1 intergenic region Proteins 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 101000785414 Homo sapiens Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000012330 Integrases Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 101000782488 Junonia coenia densovirus (isolate pBRJ/1990) Putative non-structural protein NS2 Proteins 0.000 description 1
- 101000811523 Klebsiella pneumoniae Uncharacterized 55.8 kDa protein in cps region Proteins 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 101000818409 Lactococcus lactis subsp. lactis Uncharacterized HTH-type transcriptional regulator in lacX 3'region Proteins 0.000 description 1
- 101000878851 Leptolyngbya boryana Putative Fe(2+) transport protein A Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 101000758828 Methanosarcina barkeri (strain Fusaro / DSM 804) Uncharacterized protein Mbar_A1602 Proteins 0.000 description 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 1
- 101001122401 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF3 Proteins 0.000 description 1
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101001055788 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) Pentapeptide repeat protein MfpA Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010008964 Non-Histone Chromosomal Proteins Proteins 0.000 description 1
- 102000006570 Non-Histone Chromosomal Proteins Human genes 0.000 description 1
- 101710087110 ORF6 protein Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101000740670 Orgyia pseudotsugata multicapsid polyhedrosis virus Protein C42 Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 101000769182 Photorhabdus luminescens Uncharacterized protein in pnp 3'region Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001492389 Porcine adenovirus 3 Species 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108700040121 Protein Methyltransferases Proteins 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 101000961392 Pseudescherichia vulneris Uncharacterized 29.9 kDa protein in crtE 3'region Proteins 0.000 description 1
- 101000731030 Pseudomonas oleovorans Poly(3-hydroxyalkanoate) polymerase 2 Proteins 0.000 description 1
- 101001065485 Pseudomonas putida Probable fatty acid methyltransferase Proteins 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 101000711023 Rhizobium leguminosarum bv. trifolii Uncharacterized protein in tfuA 3'region Proteins 0.000 description 1
- 101000948156 Rhodococcus erythropolis Uncharacterized 47.3 kDa protein in thcA 5'region Proteins 0.000 description 1
- 101000917565 Rhodococcus fascians Uncharacterized 33.6 kDa protein in fasciation locus Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 101001025539 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Homothallic switching endonuclease Proteins 0.000 description 1
- 101000790284 Saimiriine herpesvirus 2 (strain 488) Uncharacterized 9.5 kDa protein in DHFR 3'region Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101000936719 Streptococcus gordonii Accessory Sec system protein Asp3 Proteins 0.000 description 1
- 101000788499 Streptomyces coelicolor Uncharacterized oxidoreductase in mprA 5'region Proteins 0.000 description 1
- 101001102841 Streptomyces griseus Purine nucleoside phosphorylase ORF3 Proteins 0.000 description 1
- 101000708557 Streptomyces lincolnensis Uncharacterized 17.2 kDa protein in melC2-rnhH intergenic region Proteins 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 101000649826 Thermotoga neapolitana Putative anti-sigma factor antagonist TM1081 homolog Proteins 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101710095001 Uncharacterized protein in nifU 5'region Proteins 0.000 description 1
- 101000827562 Vibrio alginolyticus Uncharacterized protein in proC 3'region Proteins 0.000 description 1
- 101000778915 Vibrio parahaemolyticus serotype O3:K6 (strain RIMD 2210633) Uncharacterized membrane protein VP2115 Proteins 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000011130 autologous cell therapy Methods 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000000447 dimerizing effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 238000001317 epifluorescence microscopy Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 210000005133 interdigitating dendritic cell Anatomy 0.000 description 1
- 210000003535 interstitial dendritic cell Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000009438 off-target cleavage Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000033300 receptor internalization Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010374 somatic cell nuclear transfer Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000023895 stem cell maintenance Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000010648 susceptibility to HIV infection Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000003160 two-hybrid assay Methods 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2651499A CA2651499C (en) | 2006-05-25 | 2007-05-23 | Methods and compositions for ccr-5 gene inactivation |
JP2009512175A JP5551432B2 (en) | 2006-05-25 | 2007-05-23 | Methods and compositions for gene inactivation |
AU2007267874A AU2007267874B2 (en) | 2006-05-25 | 2007-05-23 | Methods and compositions for gene inactivation |
ES07795401T ES2378333T3 (en) | 2006-05-25 | 2007-05-23 | Methods and compositions for gene inactivation |
AT07795401T ATE536371T1 (en) | 2006-05-25 | 2007-05-23 | METHOD AND COMPOSITIONS FOR GENE DEACTIVATION |
EP07795401A EP2019839B1 (en) | 2006-05-25 | 2007-05-23 | Methods and compositions for gene inactivation |
HK09103505.3A HK1123313A1 (en) | 2006-05-25 | 2009-04-16 | Methods and compositions for gene inactivation |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80850106P | 2006-05-25 | 2006-05-25 | |
US60/808,501 | 2006-05-25 | ||
US84726906P | 2006-09-26 | 2006-09-26 | |
US60/847,269 | 2006-09-26 | ||
US92691107P | 2007-04-30 | 2007-04-30 | |
US60/926,911 | 2007-04-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007139982A2 true WO2007139982A2 (en) | 2007-12-06 |
WO2007139982A3 WO2007139982A3 (en) | 2008-10-16 |
Family
ID=38779263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/012588 WO2007139982A2 (en) | 2006-05-25 | 2007-05-23 | Methods and compositions for gene inactivation |
Country Status (9)
Country | Link |
---|---|
US (7) | US7951925B2 (en) |
EP (4) | EP2765195A1 (en) |
JP (2) | JP5551432B2 (en) |
AT (1) | ATE536371T1 (en) |
AU (1) | AU2007267874B2 (en) |
CA (1) | CA2651499C (en) |
ES (2) | ES2465996T3 (en) |
HK (1) | HK1123313A1 (en) |
WO (1) | WO2007139982A2 (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008153742A2 (en) * | 2007-05-23 | 2008-12-18 | Sangamo Biosciences, Inc. | Methods and compositions for increased transgene expression |
WO2009054985A1 (en) * | 2007-10-25 | 2009-04-30 | Sangamo Biosciences, Inc. | Methods and compositions for targeted integration |
WO2009151591A2 (en) | 2008-06-10 | 2009-12-17 | Sangamo Biosciences, Inc. | Methods and compositions for generation of bax- and bak-deficient cell lines |
WO2010021692A1 (en) | 2008-08-22 | 2010-02-25 | Sangamo Biosciences, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
WO2010107493A2 (en) | 2009-03-20 | 2010-09-23 | Sangamo Biosciences, Inc. | Modification of cxcr4 using engineered zinc finger proteins |
WO2011048600A1 (en) | 2009-10-21 | 2011-04-28 | Danziger Innovations Ltd. | Generating genotypic variations in plant genomes by gamete infection |
EP2441774A1 (en) | 2010-10-15 | 2012-04-18 | Fundació Privada Centre de Regulació Genòmica (CRG) | Peptides having zinc finger domains and uses thereof |
EP2522726A1 (en) | 2011-05-12 | 2012-11-14 | Fundació Privada Centre de Regulació Genòmica (CRG) | Zinc finger nucleases for p53 editing |
WO2013074999A1 (en) | 2011-11-16 | 2013-05-23 | Sangamo Biosciences, Inc. | Modified dna-binding proteins and uses thereof |
US8586526B2 (en) | 2010-05-17 | 2013-11-19 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
US8772453B2 (en) | 2010-05-03 | 2014-07-08 | Sangamo Biosciences, Inc. | Compositions for linking zinc finger modules |
US8791324B2 (en) | 2008-04-21 | 2014-07-29 | Danziger Innovations Ltd. | Plant viral expression vectors and use of same for generating genotypic variations in plant genomes |
WO2015031619A1 (en) | 2013-08-28 | 2015-03-05 | Sangamo Biosciences, Inc. | Compositions for linking dna-binding domains and cleavage domains |
US9217026B2 (en) | 2006-11-13 | 2015-12-22 | Sangamo Biosciences, Inc. | Method of inactivating a glucocorticoid receptor gene in an isolated cell |
US9249428B2 (en) | 2003-08-08 | 2016-02-02 | Sangamo Biosciences, Inc. | Methods and compositions for targeted genomic deletion |
US9394531B2 (en) | 2008-05-28 | 2016-07-19 | Sangamo Biosciences, Inc. | Compositions for linking DNA-binding domains and cleavage domains |
US9522936B2 (en) | 2014-04-24 | 2016-12-20 | Sangamo Biosciences, Inc. | Engineered transcription activator like effector (TALE) proteins |
US10724020B2 (en) | 2016-02-02 | 2020-07-28 | Sangamo Therapeutics, Inc. | Compositions for linking DNA-binding domains and cleavage domains |
US10883111B2 (en) | 2014-11-27 | 2021-01-05 | Danziger Innovations Ltd. | Nucleic acid constructs for genome editing |
EP3760719A1 (en) * | 2013-11-18 | 2021-01-06 | CRISPR Therapeutics AG | Crispr-cas system materials and methods |
WO2022003361A1 (en) | 2020-07-01 | 2022-01-06 | Imperial College Innovations Limited | Therapeutic nucleic acids, peptides and uses i |
Families Citing this family (183)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8278079B2 (en) * | 2002-11-07 | 2012-10-02 | Danisco Us Inc. | BGL6 β-glucosidase and nucleic acids encoding the same |
JP5551432B2 (en) * | 2006-05-25 | 2014-07-16 | サンガモ バイオサイエンシーズ, インコーポレイテッド | Methods and compositions for gene inactivation |
US20110014616A1 (en) * | 2009-06-30 | 2011-01-20 | Sangamo Biosciences, Inc. | Rapid screening of biologically active nucleases and isolation of nuclease-modified cells |
CA2700231C (en) * | 2007-09-27 | 2018-09-18 | Sangamo Biosciences, Inc. | Rapid in vivo identification of biologically active nucleases |
US8563314B2 (en) | 2007-09-27 | 2013-10-22 | Sangamo Biosciences, Inc. | Methods and compositions for modulating PD1 |
US11235026B2 (en) | 2007-09-27 | 2022-02-01 | Sangamo Therapeutics, Inc. | Methods and compositions for modulating PD1 |
KR101673566B1 (en) | 2008-10-29 | 2016-11-07 | 상가모 바이오사이언스 인코포레이티드 | Methods and compositions for inactivating glutamine synthetase gene expression |
US20110023143A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of neurodevelopmental genes in animals |
US20110023140A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Rabbit genome editing with zinc finger nucleases |
US20110016540A1 (en) * | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Genome editing of genes associated with trinucleotide repeat expansion disorders in animals |
US20110023153A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in alzheimer's disease |
US20110023144A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in amyotrophyic lateral sclerosis disease |
US20110023152A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genome editing of cognition related genes in animals |
US20110023146A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in secretase-associated disorders |
US20110016546A1 (en) * | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Porcine genome editing with zinc finger nucleases |
JP5681114B2 (en) | 2008-12-04 | 2015-03-04 | サンガモ バイオサイエンシーズ, インコーポレイテッド | Rat genome editing using zinc finger nuclease |
US20110023148A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genome editing of addiction-related genes in animals |
US20110016541A1 (en) * | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Genome editing of sensory-related genes in animals |
US20110023149A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in tumor suppression in animals |
US20110030072A1 (en) * | 2008-12-04 | 2011-02-03 | Sigma-Aldrich Co. | Genome editing of immunodeficiency genes in animals |
US20110023145A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in autism spectrum disorders |
US20110023156A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Feline genome editing with zinc finger nucleases |
US20110023150A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genome editing of genes associated with schizophrenia in animals |
US20110023151A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genome editing of abc transporters |
US20110023139A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in cardiovascular disease |
US20110023154A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Silkworm genome editing with zinc finger nucleases |
US20110016543A1 (en) * | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Genomic editing of genes involved in inflammation |
US20110023147A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of prion disorder-related genes in animals |
US20110023158A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Bovine genome editing with zinc finger nucleases |
US20110023141A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved with parkinson's disease |
US20110016539A1 (en) * | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Genome editing of neurotransmission-related genes in animals |
JP6215533B2 (en) | 2009-04-09 | 2017-10-18 | サンガモ セラピューティクス, インコーポレイテッド | Targeted integration into stem cells |
US8772008B2 (en) * | 2009-05-18 | 2014-07-08 | Sangamo Biosciences, Inc. | Methods and compositions for increasing nuclease activity |
EP2727600B1 (en) | 2009-07-28 | 2019-03-27 | Sangamo Therapeutics, Inc. | Zinc finger fusion proteins for repressing a huntington gene |
US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
DE112010004583T5 (en) * | 2009-11-27 | 2012-10-18 | Basf Plant Science Company Gmbh | Chimeric endonucleases and applications thereof |
WO2011086118A1 (en) * | 2010-01-14 | 2011-07-21 | Deutsches Krebsforschungszentrum | In vivo determination of the lokalization of dna double-stand breaks and application thereof |
AU2011207769B2 (en) * | 2010-01-22 | 2015-05-28 | Corteva Agriscience Llc | Targeted genomic alteration |
JP6137596B2 (en) | 2010-02-08 | 2017-05-31 | サンガモ セラピューティクス, インコーポレイテッド | Engineered truncated half-domain |
WO2011100058A1 (en) | 2010-02-09 | 2011-08-18 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
KR101880536B1 (en) | 2010-04-26 | 2018-07-23 | 상가모 테라퓨틱스, 인코포레이티드 | Genome editing of a rosa locus using zinc-finger nucleases |
US20110201118A1 (en) * | 2010-06-14 | 2011-08-18 | Iowa State University Research Foundation, Inc. | Nuclease activity of tal effector and foki fusion protein |
CA2993567C (en) | 2010-07-21 | 2022-06-28 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a t-cell receptor gene |
WO2012012738A1 (en) * | 2010-07-23 | 2012-01-26 | Sigma-Aldrich Co., Llc | Genome editing using targeting endonucleases and single-stranded nucleic acids |
WO2012015938A2 (en) * | 2010-07-27 | 2012-02-02 | The Johns Hopkins University | Obligate heterodimer variants of foki cleavage domain |
WO2012018726A1 (en) * | 2010-08-02 | 2012-02-09 | Cellectis Sa | Method for increasing double-strand break-induced gene targeting |
CA2811364C (en) | 2010-09-27 | 2022-01-04 | Sangamo Biosciences, Inc. | Methods and compositions for inhibiting viral entry into cells |
KR101930711B1 (en) | 2010-10-12 | 2018-12-19 | 더 칠드런스 호스피탈 오브 필라델피아 | Methods and compositions for treating hemophilia b |
CN102234628A (en) * | 2011-05-06 | 2011-11-09 | 中国科学院广州生物医药与健康研究院 | CCR5 deleted hematopoietic stem cell, preparation method and application thereof |
JP6185916B2 (en) | 2011-09-21 | 2017-08-23 | サンガモ セラピューティクス, インコーポレイテッド | Methods and compositions for controlling transgene expression |
US20150017728A1 (en) * | 2011-09-23 | 2015-01-15 | Iowa State University Research Foundation, Inc | Monomer architecture of tal nuclease or zinc finger nuclease for dna modification |
EP2771457B1 (en) * | 2011-10-27 | 2017-11-22 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of the hprt locus |
US9688997B2 (en) | 2011-12-29 | 2017-06-27 | Iowa State University Research Foundation, Inc. | Genetically modified plants with resistance to Xanthomonas and other bacterial plant pathogens |
GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
WO2013130824A1 (en) | 2012-02-29 | 2013-09-06 | Sangamo Biosciences, Inc. | Methods and compositions for treating huntington's disease |
WO2013169802A1 (en) | 2012-05-07 | 2013-11-14 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease-mediated targeted integration of transgenes |
LT2800811T (en) | 2012-05-25 | 2017-09-11 | The Regents Of The University Of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
AU2013289206B2 (en) | 2012-07-11 | 2018-08-09 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of lysosomal storage diseases |
US10648001B2 (en) | 2012-07-11 | 2020-05-12 | Sangamo Therapeutics, Inc. | Method of treating mucopolysaccharidosis type I or II |
EP2872154B1 (en) | 2012-07-11 | 2017-05-31 | Sangamo BioSciences, Inc. | Methods and compositions for delivery of biologics |
US20140072961A1 (en) * | 2012-07-11 | 2014-03-13 | University of Nevada, Las Vegas | Method of Genome Surgery with Paired, Permeant Endonuclease Excision |
SG11201500852WA (en) | 2012-08-29 | 2015-04-29 | Sangamo Biosciences Inc | Methods and compositions for treatment of a genetic condition |
ES2824024T3 (en) | 2012-10-10 | 2021-05-11 | Sangamo Therapeutics Inc | T cell modifying compounds and uses thereof |
US20140140969A1 (en) * | 2012-11-20 | 2014-05-22 | Sangamo Biosciences, Inc. | Methods and compositions for muscular dystrophies |
JP2016500254A (en) | 2012-12-05 | 2016-01-12 | サンガモ バイオサイエンシーズ, インコーポレイテッド | Methods and compositions for the regulation of metabolic diseases |
PL3138910T3 (en) | 2012-12-06 | 2018-01-31 | Sigma Aldrich Co Llc | Crispr-based genome modification and regulation |
WO2014130955A1 (en) | 2013-02-25 | 2014-08-28 | Sangamo Biosciences, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
JP2016519652A (en) | 2013-03-14 | 2016-07-07 | カリブー・バイオサイエンシーズ・インコーポレイテッド | Nucleic acid targeting nucleic acid compositions and methods |
CA2906970C (en) | 2013-03-21 | 2021-05-18 | Ospedale San Raffaele Srl | Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases |
CN105518146B (en) * | 2013-04-04 | 2022-07-15 | 哈佛学院校长同事会 | Therapeutic uses of genome editing with CRISPR/Cas systems |
CA2910427C (en) * | 2013-05-10 | 2024-02-20 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
WO2014186585A2 (en) | 2013-05-15 | 2014-11-20 | Sangamo Biosciences, Inc. | Methods and compositions for treatment of a genetic condition |
US10117899B2 (en) | 2013-10-17 | 2018-11-06 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells |
US9957526B2 (en) * | 2013-10-17 | 2018-05-01 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
MX2016006106A (en) | 2013-11-11 | 2016-12-09 | Sangamo Biosciences Inc | Methods and compositions for treating huntington's disease. |
RS58671B1 (en) | 2013-11-13 | 2019-06-28 | Childrens Medical Center | Nuclease-mediated regulation of gene expression |
US10081661B2 (en) | 2013-12-09 | 2018-09-25 | Sangamo Therapeutics, Inc. | Methods and compositions for genome engineering |
RS60514B1 (en) | 2014-02-03 | 2020-08-31 | Sangamo Therapeutics Inc | Methods and compositions for treatment of a beta thalessemia |
WO2015127439A1 (en) | 2014-02-24 | 2015-08-27 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease-mediated targeted integration |
KR101576728B1 (en) * | 2014-03-06 | 2015-12-10 | 가톨릭대학교 산학협력단 | Immune cell vaccine and use thereof |
JP6594891B2 (en) | 2014-03-18 | 2019-10-23 | サンガモ セラピューティクス, インコーポレイテッド | Methods and compositions for modulating zinc finger protein expression |
BR112016025849A2 (en) | 2014-05-08 | 2017-10-17 | Chdi Foundation Inc | methods and compositions for the treatment of huntington's disease |
AU2015259191B2 (en) | 2014-05-13 | 2019-03-21 | Sangamo Therapeutics, Inc. | Methods and compositions for prevention or treatment of a disease |
WO2015188065A1 (en) | 2014-06-05 | 2015-12-10 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease design |
WO2016014837A1 (en) | 2014-07-25 | 2016-01-28 | Sangamo Biosciences, Inc. | Gene editing for hiv gene therapy |
WO2016014794A1 (en) | 2014-07-25 | 2016-01-28 | Sangamo Biosciences, Inc. | Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells |
US9616090B2 (en) | 2014-07-30 | 2017-04-11 | Sangamo Biosciences, Inc. | Gene correction of SCID-related genes in hematopoietic stem and progenitor cells |
BR112017001311A2 (en) | 2014-09-07 | 2017-11-14 | Selecta Biosciences Inc | methods and compositions for attenuating the immune responses of the exon vault anti-viral transfer vector |
LT3194570T (en) | 2014-09-16 | 2021-09-27 | Sangamo Therapeutics, Inc. | Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells |
CN112553229A (en) | 2014-11-05 | 2021-03-26 | 沃雅戈治疗公司 | AADC polynucleotides for treating Parkinson's disease |
DK3218386T3 (en) | 2014-11-14 | 2021-06-07 | Voyager Therapeutics Inc | MODULATORY POLYNUCLEOTID |
KR102599909B1 (en) | 2014-11-14 | 2023-11-09 | 보이저 테라퓨틱스, 인크. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
US10201606B2 (en) | 2014-11-26 | 2019-02-12 | Miltenyi Biotec Gmbh | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases |
US10889834B2 (en) | 2014-12-15 | 2021-01-12 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing targeted transgene integration |
EP3247366A4 (en) | 2015-01-21 | 2018-10-31 | Sangamo Therapeutics, Inc. | Methods and compositions for identification of highly specific nucleases |
US20180022781A1 (en) | 2015-02-13 | 2018-01-25 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Polypeptides for engineering integrase chimeric proteins and their use in gene therapy |
JP2018513681A (en) | 2015-03-31 | 2018-05-31 | エクセリゲン サイエンティフィック, インコーポレイテッドExeligen Scientific, Inc. | Cas9 retroviral integrase and Cas9 recombinase system for targeted integration of DNA sequences into the genome of a cell or organism |
EP4335918A3 (en) * | 2015-04-03 | 2024-04-17 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
US10179918B2 (en) | 2015-05-07 | 2019-01-15 | Sangamo Therapeutics, Inc. | Methods and compositions for increasing transgene activity |
JP6873917B2 (en) | 2015-05-12 | 2021-05-19 | サンガモ セラピューティクス, インコーポレイテッド | Nuclease-mediated gene expression regulation |
WO2016183448A1 (en) * | 2015-05-14 | 2016-11-17 | University Of Southern California | Optimized gene editing utilizing a recombinant endonuclease system |
US9957501B2 (en) | 2015-06-18 | 2018-05-01 | Sangamo Therapeutics, Inc. | Nuclease-mediated regulation of gene expression |
AU2016291778B2 (en) | 2015-07-13 | 2021-05-06 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
BR112018005779A2 (en) | 2015-09-23 | 2018-10-09 | Sangamo Therapeutics, Inc. | htt repressors and uses thereof |
WO2017053729A1 (en) | 2015-09-25 | 2017-03-30 | The Board Of Trustees Of The Leland Stanford Junior University | Nuclease-mediated genome editing of primary cells and enrichment thereof |
AU2016343887B2 (en) | 2015-10-28 | 2023-04-06 | Sangamo Therapeutics, Inc. | Liver-specific constructs, factor VIII expression cassettes and methods of use thereof |
WO2017079428A1 (en) | 2015-11-04 | 2017-05-11 | President And Fellows Of Harvard College | Site specific germline modification |
WO2017091512A1 (en) | 2015-11-23 | 2017-06-01 | Sangamo Biosciences, Inc. | Methods and compositions for engineering immunity |
CA3008382A1 (en) | 2015-12-18 | 2017-06-22 | Sangamo Therapeutics, Inc. | Targeted disruption of the mhc cell receptor |
CA3008413A1 (en) | 2015-12-18 | 2017-06-22 | Sangamo Therapeutics, Inc. | Targeted disruption of the t cell receptor |
BR112018014288A2 (en) | 2016-01-15 | 2018-12-18 | Univ Minnesota | methods and compositions for the treatment of neurological disease |
AU2017267665C1 (en) | 2016-05-18 | 2023-10-05 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
CA3024449A1 (en) | 2016-05-18 | 2017-11-23 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
BR112019003100A2 (en) | 2016-08-24 | 2019-07-09 | Sangamo Therapeutics Inc | regulation of gene expression using engineered nucleases |
JP7272948B2 (en) | 2016-08-24 | 2023-05-12 | サンガモ セラピューティクス, インコーポレイテッド | engineered target-specific nucleases |
JP7256739B2 (en) | 2016-09-07 | 2023-04-12 | サンガモ セラピューティクス, インコーポレイテッド | Modulation of liver genes |
CN110022904B (en) | 2016-10-20 | 2024-04-19 | 桑格摩生物治疗股份有限公司 | Methods and compositions for treating brile disease |
CA3041668A1 (en) | 2016-10-31 | 2018-05-03 | Sangamo Therapeutics, Inc. | Gene correction of scid-related genes in hematopoietic stem and progenitor cells |
CA3061612A1 (en) | 2017-04-28 | 2018-11-01 | Acuitas Therapeutics, Inc. | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
CA3059793A1 (en) | 2017-05-03 | 2018-11-08 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene |
AU2018261003A1 (en) | 2017-05-05 | 2019-11-14 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's Disease |
US11603542B2 (en) | 2017-05-05 | 2023-03-14 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
JOP20190269A1 (en) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
US11512287B2 (en) | 2017-06-16 | 2022-11-29 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell and/or HLA receptors |
WO2019028023A2 (en) | 2017-07-31 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for assessing crispr/cas-mediated disruption or excision and crispr/cas-induced recombination with an exogenous donor nucleic acid in vivo |
BR112020001364A2 (en) | 2017-07-31 | 2020-08-11 | Regeneron Pharmaceuticals, Inc. | methods to test and modify the capacity of a crispr / cas nuclease. |
EP3585161A1 (en) | 2017-07-31 | 2020-01-01 | Regeneron Pharmaceuticals, Inc. | Assessment of crispr/cas-induced recombination with an exogenous donor nucleic acid in vivo |
WO2019075360A1 (en) | 2017-10-13 | 2019-04-18 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
BR112020008568A2 (en) | 2017-11-09 | 2020-10-06 | Sangamo Therapeutics, Inc. | genetic modification of protein gene containing cytokine-inducible sh2 (cish) |
SG11202007440YA (en) | 2018-02-08 | 2020-09-29 | Sangamo Therapeutics Inc | Engineered target specific nucleases |
US20220267420A1 (en) | 2018-02-15 | 2022-08-25 | Memorial Sloan Kettering Cancer Center | Foxp3 targeting agent compositions and methods of use for adoptive cell therapy |
KR20200139679A (en) | 2018-02-26 | 2020-12-14 | 안톨알엑스, 인크. | Immunotolerant liposomes and methods of use thereof |
KR102647714B1 (en) | 2018-03-19 | 2024-03-18 | 리제너론 파마슈티칼스 인코포레이티드 | Transcriptional regulation in animals using the CRISPR/Cas system |
CN112585276A (en) | 2018-04-05 | 2021-03-30 | 朱诺治疗学股份有限公司 | Methods of producing cells expressing recombinant receptors and related compositions |
US20210015869A1 (en) | 2018-04-05 | 2021-01-21 | Juno Therapeutics, Inc. | T cells expressing a recombinant receptor, related polynucleotides and methods |
JP7332622B2 (en) | 2018-04-18 | 2023-08-23 | サンガモ セラピューティクス, インコーポレイテッド | Zinc finger protein compositions for regulation of huntingtin (HTT) |
US11690921B2 (en) | 2018-05-18 | 2023-07-04 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
KR20210049124A (en) | 2018-08-23 | 2021-05-04 | 상가모 테라퓨틱스, 인코포레이티드 | Engineered target specific base editor |
US20220098613A1 (en) | 2018-09-12 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Reducing cd33 expression to selectively protect therapeutic cells |
KR20210060533A (en) | 2018-09-18 | 2021-05-26 | 상가모 테라퓨틱스, 인코포레이티드 | Programmed cell death 1 (PD1) specific nuclease |
WO2020069029A1 (en) | 2018-09-26 | 2020-04-02 | Emendobio Inc. | Novel crispr nucleases |
JP2022512726A (en) | 2018-10-18 | 2022-02-07 | インテリア セラピューティクス,インコーポレーテッド | Nucleic acid constructs and usage |
EP3886869A4 (en) | 2018-11-28 | 2022-07-06 | Forty Seven, Inc. | Genetically modified hspcs resistant to ablation regime |
US11453639B2 (en) | 2019-01-11 | 2022-09-27 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
US20220098621A1 (en) | 2019-02-05 | 2022-03-31 | Emendobio Inc. | Crispr compositions and methods for promoting gene editing of ribosomal protein s19 (rps19) gene |
US20220154157A1 (en) | 2019-02-06 | 2022-05-19 | Emendobio Inc. | New engineered high fidelity cas9 |
CA3133361A1 (en) | 2019-04-03 | 2020-10-08 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for insertion of antibody coding sequences into a safe harbor locus |
WO2020223535A1 (en) | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods |
WO2020223571A1 (en) | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods |
JP2022534741A (en) | 2019-05-28 | 2022-08-03 | セレクタ バイオサイエンシーズ インコーポレーテッド | Methods and compositions for attenuated antiviral transduction vector immune response |
BR112021026832A2 (en) | 2019-07-02 | 2022-05-10 | Hutchinson Fred Cancer Res | Recombinant ad35 vectors and related gene therapy enhancements |
US20230416776A1 (en) | 2019-10-08 | 2023-12-28 | Regents Of The University Of Minnesota | Crispr-mediated human genome editing with vectors |
CN114746125A (en) | 2019-11-08 | 2022-07-12 | 瑞泽恩制药公司 | CRISPR and AAV strategies for X-linked juvenile retinoschisis therapy |
WO2021108363A1 (en) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-mediated upregulation of humanized ttr allele |
WO2021195079A1 (en) | 2020-03-23 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use |
US20230181641A1 (en) | 2020-05-13 | 2023-06-15 | Juno Therapeutics, Inc. | Process for producing donor-batched cells expressing a recombinant receptor |
GB202007577D0 (en) | 2020-05-21 | 2020-07-08 | Oxford Genetics Ltd | Hdr enhancers |
GB202007578D0 (en) | 2020-05-21 | 2020-07-08 | Univ Oxford Innovation Ltd | Hdr enhancers |
WO2021234389A1 (en) | 2020-05-21 | 2021-11-25 | Oxford Genetics Limited | Hdr enhancers |
US20230183750A1 (en) | 2020-05-21 | 2023-06-15 | Oxford Genetics Limited | Hdr enhancers |
CN116234558A (en) | 2020-06-26 | 2023-06-06 | 朱诺治疗学有限公司 | Engineered T cells conditionally expressing recombinant receptors, related polynucleotides and methods |
WO2022011099A1 (en) | 2020-07-08 | 2022-01-13 | Regents Of The University Of Minnesota | Modified hexosaminidase and uses thereof |
EP4182297A1 (en) | 2020-07-16 | 2023-05-24 | Acuitas Therapeutics, Inc. | Cationic lipids for use in lipid nanoparticles |
EP4240756A1 (en) | 2020-11-04 | 2023-09-13 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
AR125199A1 (en) | 2021-03-23 | 2023-06-21 | Iovance Biotherapeutics Inc | CISH GENE EDITION OF TUMOR-INFILTRATING LYMPHOCYTES AND THEIR USES IN IMMUNOTHERAPY |
US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
AU2022379633A1 (en) | 2021-10-27 | 2024-04-11 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for expressing factor ix for hemophilia b therapy |
WO2023081756A1 (en) | 2021-11-03 | 2023-05-11 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Precise genome editing using retrons |
WO2023081900A1 (en) | 2021-11-08 | 2023-05-11 | Juno Therapeutics, Inc. | Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods |
WO2023108047A1 (en) | 2021-12-08 | 2023-06-15 | Regeneron Pharmaceuticals, Inc. | Mutant myocilin disease model and uses thereof |
WO2023122805A1 (en) | 2021-12-20 | 2023-06-29 | Vestaron Corporation | Sorbitol driven selection pressure method |
WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
WO2023150620A1 (en) | 2022-02-02 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Crispr-mediated transgene insertion in neonatal cells |
WO2023150393A2 (en) | 2022-02-07 | 2023-08-10 | Ensoma, Inc. | Inhibitor-resistant mgmt modifications and modification of mgmt-encoding nucleic acids |
WO2023150798A1 (en) | 2022-02-07 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for defining optimal treatment timeframes in lysosomal disease |
WO2023154861A1 (en) | 2022-02-11 | 2023-08-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for screening 4r tau targeting agents |
WO2023172624A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
WO2023220043A1 (en) | 2022-05-09 | 2023-11-16 | Synteny Therapeutics, Inc. | Erythroparvovirus with a modified genome for gene therapy |
WO2023220035A1 (en) | 2022-05-09 | 2023-11-16 | Synteny Therapeutics, Inc. | Erythroparvovirus compositions and methods for gene therapy |
WO2023220040A1 (en) | 2022-05-09 | 2023-11-16 | Synteny Therapeutics, Inc. | Erythroparvovirus with a modified capsid for gene therapy |
WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
WO2024044723A1 (en) | 2022-08-25 | 2024-02-29 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
WO2024073606A1 (en) | 2022-09-28 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Antibody resistant modified receptors to enhance cell-based therapies |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5422251A (en) | 1986-11-26 | 1995-06-06 | Princeton University | Triple-stranded nucleic acids |
US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
US5487994A (en) | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
US5356802A (en) | 1992-04-03 | 1994-10-18 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease |
US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
WO1995019431A1 (en) | 1994-01-18 | 1995-07-20 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
US6242568B1 (en) | 1994-01-18 | 2001-06-05 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
US5585245A (en) | 1994-04-22 | 1996-12-17 | California Institute Of Technology | Ubiquitin-based split protein sensor |
GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
JP4118327B2 (en) | 1994-08-20 | 2008-07-16 | ゲンダック・リミテッド | Improvements in or related to binding proteins for DNA recognition |
US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
GB9703369D0 (en) * | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
GB2338237B (en) | 1997-02-18 | 2001-02-28 | Actinova Ltd | In vitro peptide or protein expression library |
US6342345B1 (en) | 1997-04-02 | 2002-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of molecular interactions by reporter subunit complementation |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
AU752105B2 (en) * | 1997-12-05 | 2002-09-05 | Europaisches Laboratorium Fur Molekularbiologie (Embl) | Novel dna cloning method |
US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
US7030215B2 (en) * | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
US20030104526A1 (en) * | 1999-03-24 | 2003-06-05 | Qiang Liu | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
DE60023936T2 (en) | 1999-12-06 | 2006-05-24 | Sangamo Biosciences Inc., Richmond | METHODS OF USING RANDOMIZED ZINCFINGER PROTEIN LIBRARIES FOR IDENTIFYING GENERAL FUNCTIONS |
AU2001250774B2 (en) | 2000-02-08 | 2005-01-27 | Sangamo Biosciences, Inc. | Cells expressing zinc finger proteins for drug discovery |
US20020061512A1 (en) * | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
US20030044787A1 (en) * | 2000-05-16 | 2003-03-06 | Joung J. Keith | Methods and compositions for interaction trap assays |
JP2002060786A (en) | 2000-08-23 | 2002-02-26 | Kao Corp | Germicidal stainproofing agent for hard surface |
WO2002057308A2 (en) | 2001-01-22 | 2002-07-25 | Sangamo Biosciences, Inc. | Zinc finger polypeptides and their use |
GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
EP1421177A4 (en) | 2001-08-20 | 2006-06-07 | Scripps Research Inst | Zinc finger binding domains for cnn |
CA2474486C (en) | 2002-01-23 | 2013-05-14 | The University Of Utah Research Foundation | Targeted chromosomal mutagenesis using zinc finger nucleases |
EP2368982A3 (en) | 2002-03-21 | 2011-10-12 | Sangamo BioSciences, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
WO2003089452A2 (en) * | 2002-04-17 | 2003-10-30 | Sangamo Biosciences, Inc. | Compositions and methods for regulation of plant gamma-tocopherol methyltransferase |
EP2806025B1 (en) | 2002-09-05 | 2019-04-03 | California Institute of Technology | Use of zinc finger nucleases to stimulate gene targeting |
US20060206949A1 (en) * | 2003-01-28 | 2006-09-14 | Sylvain Arnould | Custom-made meganuclease and use thereof |
WO2005014791A2 (en) * | 2003-08-08 | 2005-02-17 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US8409861B2 (en) * | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
US20070134796A1 (en) * | 2005-07-26 | 2007-06-14 | Sangamo Biosciences, Inc. | Targeted integration and expression of exogenous nucleic acid sequences |
US7253273B2 (en) * | 2004-04-08 | 2007-08-07 | Sangamo Biosciences, Inc. | Treatment of neuropathic pain with zinc finger proteins |
EP2650365B1 (en) * | 2005-10-18 | 2016-09-14 | Precision Biosciences | Rationally designed meganucleases with altered sequence specificity and DNA-binding affinity |
JP5551432B2 (en) * | 2006-05-25 | 2014-07-16 | サンガモ バイオサイエンシーズ, インコーポレイテッド | Methods and compositions for gene inactivation |
-
2007
- 2007-05-23 JP JP2009512175A patent/JP5551432B2/en active Active
- 2007-05-23 EP EP14163013.7A patent/EP2765195A1/en not_active Withdrawn
- 2007-05-23 CA CA2651499A patent/CA2651499C/en active Active
- 2007-05-23 EP EP11164969.5A patent/EP2447279B1/en active Active
- 2007-05-23 AT AT07795401T patent/ATE536371T1/en active
- 2007-05-23 WO PCT/US2007/012588 patent/WO2007139982A2/en active Application Filing
- 2007-05-23 AU AU2007267874A patent/AU2007267874B2/en active Active
- 2007-05-23 ES ES11164969.5T patent/ES2465996T3/en active Active
- 2007-05-23 ES ES07795401T patent/ES2378333T3/en active Active
- 2007-05-23 US US11/805,707 patent/US7951925B2/en active Active
- 2007-05-23 EP EP10152257A patent/EP2206782A1/en not_active Ceased
- 2007-05-23 EP EP07795401A patent/EP2019839B1/en active Active
-
2009
- 2009-04-16 HK HK09103505.3A patent/HK1123313A1/en unknown
- 2009-10-15 US US12/587,995 patent/US20100111907A1/en not_active Abandoned
-
2011
- 2011-05-05 US US13/068,230 patent/US8524221B2/en active Active
- 2011-05-09 US US13/068,348 patent/US8569253B2/en active Active
-
2013
- 2013-10-15 US US14/054,042 patent/US9434776B2/en active Active
-
2014
- 2014-05-22 JP JP2014106579A patent/JP5944948B2/en active Active
-
2016
- 2016-07-27 US US15/220,914 patent/US20160326505A1/en not_active Abandoned
-
2018
- 2018-07-03 US US16/026,722 patent/US11648267B2/en active Active
Non-Patent Citations (19)
Title |
---|
ALKHATIB, SCIENCE, vol. 272, 1996, pages 1955 - 1958 |
ARGAST ET AL., J. MOL. BIOL., vol. 280, 1998, pages 345 - 353 |
ASHWORTH ET AL., NATURE, vol. 441, 2006, pages 656 - 659 |
BELFORT ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3379 - 3388 |
CHEVALIER, MOLEC. CELL, vol. 10, 2002, pages 895 - 905 |
DENG ET AL., NATURE, vol. 381, 1996, pages 661 - 666 |
DUJON ET AL., GENE, vol. 82, 1989, pages 115 - 118 |
EPINAT ET AL., NUCLEIC ACIDS RES, vol. 31, 2003, pages 2952 - 2962 |
FATKENHEUER ET AL., NAT. MED., vol. 11, 2005, pages 1170 - 1172 |
GIMBLE ET AL., J. MOL. BIOL., vol. 263, 1996, pages 163 - 180 |
JASIN, TRENDS GENET., vol. 12, 1996, pages 224 - 228 |
KUHMANN ET AL., J VROL., vol. 78, 2004, pages 2790 - 2807 |
LIU QIANG ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 6, 8 February 2002 (2002-02-08), pages 3850 - 3856 |
NILSSON ET AL., J GENE MED, vol. 6, 2004, pages 631 - 641 |
NILSSON ET AL., MOL THER, vol. 9, 2004, pages 377 - 388 |
PAQUES ET AL., CURRENT GENE THERAPY, vol. 7, 2007, pages 49 - 66 |
PERLER ET AL., NUCLEIC ACIDS RES., vol. 22, 1994, pages 1125 - 1127 |
ROBERTS ET AL., NUCLEIC ACIDS RES., vol. 31, 2003, pages 418 - 420 |
SAMSON, NATURE, vol. 382, 1996, pages 722 - 725 |
Cited By (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9752140B2 (en) | 2003-08-08 | 2017-09-05 | Sangamo Therapeutics, Inc. | Methods and compostions for targeted genomic deletion |
US9249428B2 (en) | 2003-08-08 | 2016-02-02 | Sangamo Biosciences, Inc. | Methods and compositions for targeted genomic deletion |
US10717993B2 (en) | 2006-05-25 | 2020-07-21 | Sangamo Therapeutics, Inc. | Methods and compositions for increased transgene expression |
US11884930B2 (en) | 2006-11-13 | 2024-01-30 | Sangamo Biosciences, Inc. | Method of inactivating a glucocorticoid receptor gene in an isolated cell |
US10907175B2 (en) | 2006-11-13 | 2021-02-02 | Sangamo Therapeutics, Inc. | Isolated human cell with an inactivated glucocorticoid receptor gene |
US9217026B2 (en) | 2006-11-13 | 2015-12-22 | Sangamo Biosciences, Inc. | Method of inactivating a glucocorticoid receptor gene in an isolated cell |
WO2008153742A2 (en) * | 2007-05-23 | 2008-12-18 | Sangamo Biosciences, Inc. | Methods and compositions for increased transgene expression |
WO2008153742A3 (en) * | 2007-05-23 | 2009-02-05 | Sangamo Biosciences Inc | Methods and compositions for increased transgene expression |
JP2010527606A (en) * | 2007-05-23 | 2010-08-19 | サンガモ バイオサイエンシーズ, インコーポレイテッド | Methods and compositions for enhancing transgene expression |
AU2008262487B2 (en) * | 2007-05-23 | 2013-10-31 | Sangamo Therapeutics, Inc. | Methods and compositions for increased transgene expression |
EP2597155A1 (en) * | 2007-10-25 | 2013-05-29 | Sangamo BioSciences, Inc. | Methods and compositions for targeted integration |
WO2009054985A1 (en) * | 2007-10-25 | 2009-04-30 | Sangamo Biosciences, Inc. | Methods and compositions for targeted integration |
US8936936B2 (en) | 2007-10-25 | 2015-01-20 | Sangamo Biosciences, Inc. | Methods and compositions for targeted integration |
EP2936976A1 (en) | 2008-04-21 | 2015-10-28 | Danziger Innovations Ltd. | Plant viral expression vectors and use of same for generating genotypic variations in plant genomes |
US8791324B2 (en) | 2008-04-21 | 2014-07-29 | Danziger Innovations Ltd. | Plant viral expression vectors and use of same for generating genotypic variations in plant genomes |
US9982245B2 (en) | 2008-05-28 | 2018-05-29 | Sangamo Therapeutics, Inc. | Compositions for linking DNA-binding domains and cleavage domains |
US11608492B2 (en) | 2008-05-28 | 2023-03-21 | Sangamo Therapeutics, Inc. | Compositions for linking DNA-binding domains and cleavage domains |
US10822599B2 (en) | 2008-05-28 | 2020-11-03 | Sangamo Therapeutics, Inc. | Compositions for linking DNA-binding domains and cleavage domains |
US9394531B2 (en) | 2008-05-28 | 2016-07-19 | Sangamo Biosciences, Inc. | Compositions for linking DNA-binding domains and cleavage domains |
WO2009151591A2 (en) | 2008-06-10 | 2009-12-17 | Sangamo Biosciences, Inc. | Methods and compositions for generation of bax- and bak-deficient cell lines |
JP2011522564A (en) * | 2008-06-10 | 2011-08-04 | サンガモ バイオサイエンシーズ, インコーポレイテッド | Methods and compositions for the generation of Bax- and Bak-deficient cell lines |
EP2910568A2 (en) | 2008-06-10 | 2015-08-26 | Sangamo BioSciences, Inc. | Methods and compositions for generation of BAX- and BAK-deficient cell lines |
US8597912B2 (en) | 2008-06-10 | 2013-12-03 | Sangamo Biosciences, Inc. | Methods and compositions for generation of Bax-and Bak-deficient cell lines |
US10113207B2 (en) | 2008-08-22 | 2018-10-30 | Sangamo Therapeutics, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
AU2009283194B2 (en) * | 2008-08-22 | 2014-10-16 | Sangamo Therapeutics, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
EP2789691A1 (en) | 2008-08-22 | 2014-10-15 | Sangamo BioSciences, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
US9631186B2 (en) | 2008-08-22 | 2017-04-25 | Sangamo Biosciences, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
US9200266B2 (en) | 2008-08-22 | 2015-12-01 | Sangamo Biosciences, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
US8703489B2 (en) | 2008-08-22 | 2014-04-22 | Sangamo Biosciences, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
US10689717B2 (en) | 2008-08-22 | 2020-06-23 | Sangamo Therapeutics, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
WO2010021692A1 (en) | 2008-08-22 | 2010-02-25 | Sangamo Biosciences, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
US11149321B2 (en) | 2008-08-22 | 2021-10-19 | Sangamo Therapeutics, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
US8871905B2 (en) | 2009-03-20 | 2014-10-28 | Sangamo Biosciences, Inc. | Modification of CXCR4 using engineered zinc finger proteins |
WO2010107493A2 (en) | 2009-03-20 | 2010-09-23 | Sangamo Biosciences, Inc. | Modification of cxcr4 using engineered zinc finger proteins |
JP2016011302A (en) * | 2009-03-20 | 2016-01-21 | サンガモ バイオサイエンシーズ, インコーポレイテッド | Modification of cxcr4 using engineered zinc finger proteins |
EP2408921A4 (en) * | 2009-03-20 | 2012-10-10 | Sangamo Biosciences Inc | Modification of cxcr4 using engineered zinc finger proteins |
JP2012520675A (en) * | 2009-03-20 | 2012-09-10 | サンガモ バイオサイエンシーズ, インコーポレイテッド | Modification of CXCR4 using modified zinc finger protein |
EP2408921A2 (en) * | 2009-03-20 | 2012-01-25 | Sangamo BioSciences, Inc. | Modification of cxcr4 using engineered zinc finger proteins |
US9717759B2 (en) | 2009-03-20 | 2017-08-01 | Sangamo Therapeutics, Inc. | Modification of CXCR4 using engineered zinc finger proteins |
WO2011048600A1 (en) | 2009-10-21 | 2011-04-28 | Danziger Innovations Ltd. | Generating genotypic variations in plant genomes by gamete infection |
US9476060B2 (en) | 2009-10-21 | 2016-10-25 | Danziger Innovations Ltd. | Generating genotypic variations in plant genomes by gamete infection |
EP3636766A1 (en) | 2010-05-03 | 2020-04-15 | Sangamo Therapeutics, Inc. | Compositions for linking zinc finger modules |
US9163245B2 (en) | 2010-05-03 | 2015-10-20 | Sangamo Biosciences, Inc. | Compositions for linking zinc finger modules |
US8772453B2 (en) | 2010-05-03 | 2014-07-08 | Sangamo Biosciences, Inc. | Compositions for linking zinc finger modules |
US9783827B2 (en) | 2010-05-17 | 2017-10-10 | Sangamo Therapeutics, Inc. | DNA-binding proteins and uses thereof |
US8586526B2 (en) | 2010-05-17 | 2013-11-19 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
US9322005B2 (en) | 2010-05-17 | 2016-04-26 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
US8912138B2 (en) | 2010-05-17 | 2014-12-16 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
US10253333B2 (en) | 2010-05-17 | 2019-04-09 | Sangamo Therapeutics, Inc. | DNA-binding proteins and uses thereof |
US11661612B2 (en) | 2010-05-17 | 2023-05-30 | Sangamo Therapeutics, Inc. | DNA-binding proteins and uses thereof |
US9493750B2 (en) | 2010-05-17 | 2016-11-15 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
EP2441774A1 (en) | 2010-10-15 | 2012-04-18 | Fundació Privada Centre de Regulació Genòmica (CRG) | Peptides having zinc finger domains and uses thereof |
WO2012049332A1 (en) | 2010-10-15 | 2012-04-19 | Fundació Privada Centre De Regulació Genòmica | Peptides and uses |
EP2522726A1 (en) | 2011-05-12 | 2012-11-14 | Fundació Privada Centre de Regulació Genòmica (CRG) | Zinc finger nucleases for p53 editing |
US9458205B2 (en) | 2011-11-16 | 2016-10-04 | Sangamo Biosciences, Inc. | Modified DNA-binding proteins and uses thereof |
WO2013074999A1 (en) | 2011-11-16 | 2013-05-23 | Sangamo Biosciences, Inc. | Modified dna-binding proteins and uses thereof |
EP3988654A1 (en) | 2013-08-28 | 2022-04-27 | Sangamo Therapeutics, Inc. | Compositions for linking dna-binding domains and cleavage domains |
WO2015031619A1 (en) | 2013-08-28 | 2015-03-05 | Sangamo Biosciences, Inc. | Compositions for linking dna-binding domains and cleavage domains |
EP3591045A1 (en) | 2013-08-28 | 2020-01-08 | Sangamo Therapeutics, Inc. | Compositions for linking dna-binding domains and cleavage domains |
EP3760719A1 (en) * | 2013-11-18 | 2021-01-06 | CRISPR Therapeutics AG | Crispr-cas system materials and methods |
US9522936B2 (en) | 2014-04-24 | 2016-12-20 | Sangamo Biosciences, Inc. | Engineered transcription activator like effector (TALE) proteins |
US10883111B2 (en) | 2014-11-27 | 2021-01-05 | Danziger Innovations Ltd. | Nucleic acid constructs for genome editing |
EP3769775A2 (en) | 2016-02-02 | 2021-01-27 | Sangamo Therapeutics, Inc. | Compositions for linking dna-binding domains and cleavage domains |
US10724020B2 (en) | 2016-02-02 | 2020-07-28 | Sangamo Therapeutics, Inc. | Compositions for linking DNA-binding domains and cleavage domains |
US11920169B2 (en) | 2016-02-02 | 2024-03-05 | Sangamo Therapeutics, Inc. | Compositions for linking DNA-binding domains and cleavage domains |
WO2022003363A1 (en) | 2020-07-01 | 2022-01-06 | Imperial College Innovations Limited | Active delivery of nucleic acids and peptides, methods and uses |
WO2022003362A1 (en) | 2020-07-01 | 2022-01-06 | Imperial College Innovations Limited | Therapeutic nucleic acids, peptides and uses ii |
WO2022003361A1 (en) | 2020-07-01 | 2022-01-06 | Imperial College Innovations Limited | Therapeutic nucleic acids, peptides and uses i |
Also Published As
Publication number | Publication date |
---|---|
US7951925B2 (en) | 2011-05-31 |
HK1123313A1 (en) | 2009-06-12 |
US8569253B2 (en) | 2013-10-29 |
EP2447279A1 (en) | 2012-05-02 |
EP2447279B1 (en) | 2014-04-09 |
CA2651499A1 (en) | 2007-12-06 |
US20120309091A1 (en) | 2012-12-06 |
US20080159996A1 (en) | 2008-07-03 |
US11648267B2 (en) | 2023-05-16 |
ES2465996T3 (en) | 2014-06-09 |
EP2019839B1 (en) | 2011-12-07 |
JP2014221041A (en) | 2014-11-27 |
EP2206782A1 (en) | 2010-07-14 |
US8524221B2 (en) | 2013-09-03 |
US20140127811A1 (en) | 2014-05-08 |
EP2019839A2 (en) | 2009-02-04 |
JP2009538141A (en) | 2009-11-05 |
CA2651499C (en) | 2015-06-30 |
US20100111907A1 (en) | 2010-05-06 |
JP5551432B2 (en) | 2014-07-16 |
JP5944948B2 (en) | 2016-07-05 |
US20120308528A1 (en) | 2012-12-06 |
US20180312826A1 (en) | 2018-11-01 |
ES2378333T3 (en) | 2012-04-11 |
ATE536371T1 (en) | 2011-12-15 |
US9434776B2 (en) | 2016-09-06 |
WO2007139982A3 (en) | 2008-10-16 |
EP2765195A1 (en) | 2014-08-13 |
AU2007267874B2 (en) | 2012-03-15 |
AU2007267874A1 (en) | 2007-12-06 |
US20160326505A1 (en) | 2016-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11648267B2 (en) | Methods and compositions for gene inactivation | |
US20230346844A1 (en) | Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases | |
US11884930B2 (en) | Method of inactivating a glucocorticoid receptor gene in an isolated cell | |
JP5932632B2 (en) | Modification of CXCR4 using modified zinc finger protein | |
EP2597155B1 (en) | Methods and compositions for targeted integration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07795401 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2651499 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007267874 Country of ref document: AU Ref document number: 2007795401 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009512175 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007267874 Country of ref document: AU Date of ref document: 20070523 Kind code of ref document: A |